This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Cytori Therapeutics

BOSTON ( TheStreet) -- I hope everyone will join me at 11 a.m. ET today for the first-ever Biotech Stock Mailbag Live Chat. [Check <a href=""><i>TheStreet's</i> web site</a> for a link when the chat goes live.]

I'll answer your questions and respond to your comments in what I hope will be an informative and fun discussion about the current state of the biotech investment sector. The live chat is particularly timely with the ASCO abstract release on Wednesday, so definitely bring your cancer drug stock questions. A reader asked me to throw some biotech stock polls into the live chat, so yes, there will also be polls galore.

This week's email and tweets:

Fred B. asks, "Any comments on Cytori Therapeutics(CYTX - Get Report) announcement about using fat cells for regeneration."

Yes, let's talk about Cytori again, which is newsworthy after this week's press release concerning another "independent clinical study" (that's Cytori's description) of stem cell-enriched fat grafting in breast reconstruction surgery.

Twenty-three women requiring breast reconstruction surgery underwent a liposuction procedure to remove fat from the abdomen or thighs. The fat was then processed using Cytori's Celution System device, which extracts stem cells that reside naturally in fat tissue. Once the stem cells are extracted and enriched by the Celution device, they are mixed back into the fat. Surgeons inject this stem cell-enriched fat graft into the patients' breasts as part of the reconstruction procedure.

The results of this study, conducted in the U.K., showed that 19 of the 23 women, or 82%, were satisfied with the results of their breast reconstruction. Surgeons were also happy with the results, according to Cytori.

The results in the Cytori press release sound promising, but let's think about this study for a second. What's responsible for causing the satisfaction observed by these patients? Is it the stem cell-enriched fat? Or is it just the fat itself?

It's an important question scientifically and financially. A study proving that "enriched" stem cells help fat-tissue grafts implant better or prevents fat grafts from being reabsorbed into the body would be a significant scientific finding and advance the nascent field of stem cell research.

Such a finding could also be a business boon to Cytori because it would conceivably convince regulators to allow the company to make specific medical claims about the stem cells that pop out the back of its Celution System device. With that kind of regulatory approval, Cytori could sell a lot more Celution System machines and maybe even get insurers to reimburse for the procedures.

Unfortunately, the U.K. study of those 23 women doesn't answer this important question at all because the study fails to compare the efficacy and safety of breast reconstruction surgery using Cytori's expensive stem cell-enriched fat tissue to the same procedure using standard, relatively inexpensive, fat tissue (which by the way, also contains stem cells, just not processed through a machine.)
1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BPAX $55.05 -1.24%
CYTX $0.37 2.24%
INCY $115.41 3.30%
MRK $53.72 0.45%
VRTX $131.97 -0.87%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs